<DOC>
	<DOCNO>NCT02041247</DOCNO>
	<brief_summary>The purpose study evaluate protective effect VAC-3S control HIV patient receive standard care antiretroviral treatment .</brief_summary>
	<brief_title>Assessment VAC-3S Therapeutic Properties When Combined With Standard ART Course HIV-1 Infection</brief_title>
	<detailed_description />
	<criteria>1 . Documented HIV1 infection , 2 . Adults &gt; 18 &lt; 60 year age , 3 . Able willing comply protocol , include availability schedule study visit , 4 . Provided sign write informed consent , 5 . Meets study screen physical , medical history laboratory assessment ( define ) , 6 . On stable antiretroviral therapy consistent current standard care least 12 month prior study screen , 7 . Plasma HIV RNA &lt; 50 cps/mL previous 12 month , 8 . CD4+ T cell count screen &gt; 200 &lt; 500 cells/mm3 , 9 . Adequate hematology , biochemistry , metabolic blood test define less grade 2 accord Division AIDS Adverse Events ( See Appendix 23.1 ) , except numeration CD4 numeration lymphocyte , 10 . Adequate hepatic renal function define less Grade 2 accord Division AIDS Adverse Events ( See Appendix 23.1 ) , 11 . Female patient childbearing age one document negative blood pregnancy test Screening Visit 1/Month 0 ; Female patient childbearing potential must receive two form effective contraception must willing use throughout study duration . These include oral , transdermal , systemic implant contraception birth control , intrauterine device ( IUD ) , abstinence double barrier method diaphragm spermicidal gel recommend double barrier method , 12 . Affiliated National Medical Insurance System , 13 . Believed investigator able willing comply requirement study protocol available schedule visit study site . 1 . Not meet inclusion criterion list , 2 . Administration investigational drug device within 28 day prior screen , 3 . Prior history AIDSdefining event past 5 year , 4 . Active coinfection either Hepatitis C Virus ( HCV ) Hepatitis B Virus ( HBV ) active viral hepatitis coinfection , 5 . Any acute clinically significant infection within past month , 6 . Known allergy intolerance component VAC3S document medical record via patient interview , 7 . Chronic active liver disease document follow laboratory assessment : ultrasound , clinical assessment , liver biopsy equivalent noninvasive method , 8 . Receipt known vaccination within past 1 month prior screen , 9 . Receipt agent past 12 month exerts know immunological effect ( e.g . include limited IL2 , IL7 , growth hormoneâ€¦ ) , 10 . Patients Insulin Dependent Diabetes Mellitus , patient receive antidiabetic treatment , anticoagulant ( exclude daily `` babydose '' aspirin ) daily NSAIDs within one week study enrollment , 11 . Receipt contraindicate medication list Appendix 23.2 , 12 . History active autoimmune disease , 13 . Acute chronic psychiatric condition opinion investigator would need continual psychological support and/or medication incompatible study participation , 14 . Patients contraindication intramuscular injection include , limited , patient thrombocytopenia and/or anomaly coagulation system , 15 . Any uncontrolled chronic acute condition opinion investigator would compromise safety patient ability properly administer study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>